REDWOOD CITY, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (`Soleno`) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter and nine months ended September 30, 2019. `We continue to be pleased with the progress of patient enrollment in our ongoing Phase III clinical trial, DESTINY PWS, evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader Willi Syndrome (PWS), and remain on track to announce top-line data in the first half of 2020,` said Anish Bhatnagar, M.D., Chief...
|
